This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
DPDPE
Accession Number
DB08861
Type
Small Molecule
Groups
Experimental
Description

A heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.

Structure
Thumb
Synonyms
  • (D-Pen2,D-Pen5)-Enkephalin
  • [D-Pen2-D-Pen5]-enkephaline
  • 2,5-Pen-enkephalin
  • cyclo-[D-Pen2,5]-enkephalin
  • D-penicillamine-(2,5)-enkephalin
  • L-tyrosyl-3-mercapto-D-valylglycyl-L-phenylalanyl-3-mercapto-D-valine, cyclic (2-5)-disulfide
Categories
UNII
Not Available
CAS number
88373-73-3
Weight
Average: 645.79
Monoisotopic: 645.229090964
Chemical Formula
C30H39N5O7S2
InChI Key
MCMMCRYPQBNCPH-WMIMKTLMSA-N
InChI
InChI=1S/C30H39N5O7S2/c1-29(2)23(34-25(38)20(31)14-18-10-12-19(36)13-11-18)27(40)32-16-22(37)33-21(15-17-8-6-5-7-9-17)26(39)35-24(28(41)42)30(3,4)44-43-29/h5-13,20-21,23-24,36H,14-16,31H2,1-4H3,(H,32,40)(H,33,37)(H,34,38)(H,35,39)(H,41,42)/t20-,21-,23-,24-/m0/s1
IUPAC Name
(4S,7S,13S)-13-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-7-benzyl-3,3,14,14-tetramethyl-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxylic acid
SMILES
CC1(C)SSC(C)(C)[[email protected]@H](NC(=O)[[email protected]@H](N)CC2=CC=C(O)C=C2)C(=O)NCC(=O)N[[email protected]@H](CC2=CC=CC=C2)C(=O)N[[email protected]]1C(O)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of DPDPE.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of DPDPE.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of DPDPE.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with DPDPE.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when DPDPE is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with DPDPE.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with DPDPE.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when DPDPE is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with DPDPE.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with DPDPE.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with DPDPE.Approved, Investigational
AlaproclateDPDPE may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with DPDPE.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when DPDPE is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with DPDPE.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of DPDPE.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when DPDPE is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with DPDPE.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when DPDPE is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with DPDPE.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when DPDPE is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when DPDPE is combined with Amiloride.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with DPDPE.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when DPDPE is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of DPDPE which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with DPDPE.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when DPDPE is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when DPDPE is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of DPDPE.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with DPDPE.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with DPDPE.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when DPDPE is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with DPDPE.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with DPDPE.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with DPDPE.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with DPDPE.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Azaperone.Investigational, Vet Approved
AzelastineDPDPE may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when DPDPE is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when DPDPE is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with DPDPE.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with DPDPE.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when DPDPE is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when DPDPE is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when DPDPE is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with DPDPE.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with DPDPE.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of DPDPE.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with DPDPE.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with DPDPE.Approved, Investigational
BL-1020BL-1020 may increase the hypotensive activities of DPDPE.Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with DPDPE.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when DPDPE is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Approved
BrofaromineThe risk or severity of adverse effects can be increased when DPDPE is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with DPDPE.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when DPDPE is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when DPDPE is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when DPDPE is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when DPDPE is combined with Brotizolam.Approved, Investigational, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when DPDPE is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with DPDPE.Approved, Investigational
BuprenorphineDPDPE may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with DPDPE.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with DPDPE.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when DPDPE is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when DPDPE is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when DPDPE is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with DPDPE.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with DPDPE.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with DPDPE.Approved, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with DPDPE.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when DPDPE is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Canrenone.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with DPDPE.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when DPDPE is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with DPDPE.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when DPDPE is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Caroxazone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when DPDPE is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with DPDPE.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with DPDPE.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with DPDPE.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with DPDPE.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when DPDPE is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when DPDPE is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with DPDPE.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of DPDPE.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of DPDPE.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with DPDPE.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with DPDPE.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when DPDPE is combined with Cicletanine.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with DPDPE.Approved, Vet Approved
CitalopramDPDPE may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when DPDPE is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when DPDPE is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when DPDPE is combined with Clobazam.Approved, Illicit
ClofenamideThe risk or severity of adverse effects can be increased when DPDPE is combined with Clofenamide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with DPDPE.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when DPDPE is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when DPDPE is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when DPDPE is combined with Clonidine.Approved
ClopamideThe risk or severity of adverse effects can be increased when DPDPE is combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when DPDPE is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with DPDPE.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when DPDPE is combined with Clorexolone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when DPDPE is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with DPDPE.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with DPDPE.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with DPDPE.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when DPDPE is combined with Conivaptan.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when DPDPE is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with DPDPE.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when DPDPE is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with DPDPE.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when DPDPE is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when DPDPE is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when DPDPE is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with DPDPE.Approved
DapoxetineDPDPE may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with DPDPE.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with DPDPE.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with DPDPE.Approved
DesipramineThe risk or severity of adverse effects can be increased when DPDPE is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when DPDPE is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when DPDPE is combined with Desmopressin.Approved
DesvenlafaxineDPDPE may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when DPDPE is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when DPDPE is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with DPDPE.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with DPDPE.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of DPDPE.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with DPDPE.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with DPDPE.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with DPDPE.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with DPDPE.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with DPDPE.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when DPDPE is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of DPDPE.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when DPDPE is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with DPDPE.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with DPDPE.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with DPDPE.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when DPDPE is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with DPDPE.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with DPDPE.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when DPDPE is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when DPDPE is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when DPDPE is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Approved, Vet Approved
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with DPDPE.Experimental, Illicit
DuloxetineDPDPE may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with DPDPE.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with DPDPE.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when DPDPE is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when DPDPE is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when DPDPE is combined with Efonidipine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when DPDPE is combined with Eltanolone.Investigational
EluxadolineDPDPE may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with DPDPE.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with DPDPE.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when DPDPE is combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Eplerenone.Approved
EscitalopramDPDPE may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with DPDPE.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with DPDPE.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when DPDPE is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with DPDPE.Experimental
EthanolDPDPE may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with DPDPE.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with DPDPE.Approved
EthosuximideThe risk or severity of adverse effects can be increased when DPDPE is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when DPDPE is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when DPDPE is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with DPDPE.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when DPDPE is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with DPDPE.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with DPDPE.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when DPDPE is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when DPDPE is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when DPDPE is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with DPDPE.Approved
EtoperidoneDPDPE may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with DPDPE.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with DPDPE.Experimental
EzogabineThe risk or severity of adverse effects can be increased when DPDPE is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when DPDPE is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with DPDPE.Approved, Illicit, Withdrawn
FenquizoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Fenquizone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with DPDPE.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with DPDPE.Approved
FexofenadineThe risk or severity of adverse effects can be increased when DPDPE is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when DPDPE is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with DPDPE.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when DPDPE is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with DPDPE.Approved, Illicit
FluoxetineDPDPE may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with DPDPE.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with DPDPE.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with DPDPE.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with DPDPE.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when DPDPE is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with DPDPE.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when DPDPE is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with DPDPE.Approved, Illicit, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when DPDPE is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with DPDPE.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when DPDPE is combined with Gabapentin Enacarbil.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with DPDPE.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with DPDPE.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with DPDPE.Approved, Illicit, Investigational
GepefrineGepefrine may increase the analgesic activities of DPDPE.Experimental
GepironeThe risk or severity of adverse effects can be increased when DPDPE is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with DPDPE.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with DPDPE.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when DPDPE is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with DPDPE.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with DPDPE.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with DPDPE.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when DPDPE is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with DPDPE.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with DPDPE.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with DPDPE.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with DPDPE.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when DPDPE is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when DPDPE is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneDPDPE may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when DPDPE is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with DPDPE.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of DPDPE.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with DPDPE.Approved
IbopamineThe risk or severity of adverse effects can be increased when DPDPE is combined with Ibopamine.Experimental
IloperidoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when DPDPE is combined with Imipramine.Approved
IndalpineDPDPE may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when DPDPE is combined with Indapamide.Approved
IndiplonThe risk or severity of adverse effects can be increased when DPDPE is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of DPDPE.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with DPDPE.Approved
IproclozideThe risk or severity of adverse effects can be increased when DPDPE is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when DPDPE is combined with Iproniazid.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when DPDPE is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with DPDPE.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when DPDPE is combined with Isosorbide.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with DPDPE.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with DPDPE.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with DPDPE.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when DPDPE is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when DPDPE is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with DPDPE.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when DPDPE is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when DPDPE is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when DPDPE is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with DPDPE.Approved, Investigational
LevomilnacipranDPDPE may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with DPDPE.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with DPDPE.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of DPDPE.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with DPDPE.Approved
LofentanilThe risk or severity of adverse effects can be increased when DPDPE is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when DPDPE is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when DPDPE is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with DPDPE.Approved
LormetazepamThe risk or severity of adverse effects can be increased when DPDPE is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with DPDPE.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with DPDPE.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when DPDPE is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when DPDPE is combined with Maprotiline.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with DPDPE.Experimental
MebanazineThe risk or severity of adverse effects can be increased when DPDPE is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when DPDPE is combined with Mebicar.Experimental
MebutizideThe risk or severity of adverse effects can be increased when DPDPE is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with DPDPE.Approved
MeclizineThe risk or severity of adverse effects can be increased when DPDPE is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when DPDPE is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when DPDPE is combined with Medetomidine.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when DPDPE is combined with Mefruside.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with DPDPE.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Melperone.Approved, Investigational
MephedroneMephedrone may increase the analgesic activities of DPDPE.Investigational
MephentermineMephentermine may increase the analgesic activities of DPDPE.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with DPDPE.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with DPDPE.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when DPDPE is combined with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when DPDPE is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with DPDPE.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when DPDPE is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with DPDPE.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with DPDPE.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of DPDPE.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with DPDPE.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with DPDPE.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with DPDPE.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when DPDPE is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when DPDPE is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with DPDPE.Approved
MethotrimeprazineDPDPE may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with DPDPE.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of DPDPE.Experimental
MethscopolamineThe risk or severity of adverse effects can be increased when Methscopolamine is combined with DPDPE.Approved
MethsuximideThe risk or severity of adverse effects can be increased when DPDPE is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when DPDPE is combined with Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with DPDPE.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of DPDPE.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with DPDPE.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with DPDPE.Approved
MeticraneThe risk or severity of adverse effects can be increased when DPDPE is combined with Meticrane.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with DPDPE.Approved
MetolazoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Metolazone.Approved
MetyrosineDPDPE may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with DPDPE.Approved, Illicit
MidomafetamineMidomafetamine may increase the analgesic activities of DPDPE.Experimental, Illicit, Investigational
MilnacipranDPDPE may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when DPDPE is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Approved, Investigational
MirtazapineDPDPE may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may increase the analgesic activities of DPDPE.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when DPDPE is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with DPDPE.Approved
MoricizineMoricizine may increase the hypotensive activities of DPDPE.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with DPDPE.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when DPDPE is combined with Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with DPDPE.Approved
NaltrexoneThe therapeutic efficacy of DPDPE can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneDPDPE may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideThe risk or severity of adverse effects can be increased when DPDPE is combined with Nialamide.Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with DPDPE.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with DPDPE.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when DPDPE is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when DPDPE is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when DPDPE is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with DPDPE.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when DPDPE is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with DPDPE.Approved
OpiumThe risk or severity of adverse effects can be increased when DPDPE is combined with Opium.Approved, Illicit
OrphenadrineDPDPE may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with DPDPE.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with DPDPE.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with DPDPE.Approved
OxethazaineThe risk or severity of adverse effects can be increased when DPDPE is combined with Oxethazaine.Approved, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with DPDPE.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with DPDPE.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with DPDPE.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with DPDPE.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with DPDPE.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with DPDPE.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with DPDPE.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with DPDPE.Approved
PamabromThe risk or severity of adverse effects can be increased when DPDPE is combined with Pamabrom.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with DPDPE.Approved
ParaldehydeDPDPE may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when DPDPE is combined with Pargyline.Approved
ParoxetineDPDPE may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with DPDPE.Approved
PenfluridolThe risk or severity of adverse effects can be increased when DPDPE is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with DPDPE.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with DPDPE.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with DPDPE.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Approved
PerazineThe risk or severity of adverse effects can be increased when DPDPE is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when DPDPE is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with DPDPE.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with DPDPE.Approved
PhenazocineThe risk or severity of adverse effects can be increased when DPDPE is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when DPDPE is combined with Phenelzine.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with DPDPE.Experimental
PhenibutThe risk or severity of adverse effects can be increased when DPDPE is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when DPDPE is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with DPDPE.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when DPDPE is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when DPDPE is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when DPDPE is combined with Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of DPDPE.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when DPDPE is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with DPDPE.Approved
PipamperoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with DPDPE.Approved
PipotiazineThe risk or severity of adverse effects can be increased when DPDPE is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with DPDPE.Approved
PiretanideThe risk or severity of adverse effects can be increased when DPDPE is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when DPDPE is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when DPDPE is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when DPDPE is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when DPDPE is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when DPDPE is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when DPDPE is combined with Pomalidomide.Approved
PotassiumThe risk or severity of adverse effects can be increased when DPDPE is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when DPDPE is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleDPDPE may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when DPDPE is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with DPDPE.Approved, Illicit
PregabalinThe therapeutic efficacy of DPDPE can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with DPDPE.Approved
PrimidoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with DPDPE.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when DPDPE is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with DPDPE.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with DPDPE.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with DPDPE.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when DPDPE is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when DPDPE is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with DPDPE.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with DPDPE.Approved, Vet Approved
PropericiazinePropericiazine may increase the hypotensive activities of DPDPE.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of DPDPE.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with DPDPE.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with DPDPE.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when DPDPE is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when DPDPE is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when DPDPE is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with DPDPE.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of DPDPE.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with DPDPE.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with DPDPE.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with DPDPE.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when DPDPE is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when DPDPE is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when DPDPE is combined with Ramelteon.Approved, Investigational
RamosetronDPDPE may increase the constipating activities of Ramosetron.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when DPDPE is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with DPDPE.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with DPDPE.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with DPDPE.Approved, Investigational
RilpivirineThe serum concentration of DPDPE can be decreased when it is combined with Rilpivirine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with DPDPE.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when DPDPE is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of DPDPE.Investigational
RolofyllineThe risk or severity of adverse effects can be increased when DPDPE is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when DPDPE is combined with Romifidine.Vet Approved
RopiniroleDPDPE may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with DPDPE.Approved
RotigotineDPDPE may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with DPDPE.Approved
SafrazineThe risk or severity of adverse effects can be increased when DPDPE is combined with Safrazine.Withdrawn
ScopolamineThe risk or severity of adverse effects can be increased when DPDPE is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with DPDPE.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when DPDPE is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when DPDPE is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with DPDPE.Approved, Investigational, Withdrawn
SertralineDPDPE may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with DPDPE.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with DPDPE.Approved
SpiradolineThe risk or severity of adverse effects can be increased when DPDPE is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when DPDPE is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of DPDPE.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with DPDPE.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with DPDPE.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when DPDPE is combined with Sultopride.Experimental
SuvorexantDPDPE may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when DPDPE is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Approved
TasimelteonThe risk or severity of adverse effects can be increased when DPDPE is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with DPDPE.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when DPDPE is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when DPDPE is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when DPDPE is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with DPDPE.Investigational
ThalidomideDPDPE may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when DPDPE is combined with Theobromine.Approved, Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with DPDPE.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of DPDPE.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of DPDPE.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with DPDPE.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of DPDPE.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with DPDPE.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with DPDPE.Approved
TiagabineThe risk or severity of adverse effects can be increased when DPDPE is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when DPDPE is combined with Tiapride.Approved, Investigational
TicrynafenThe risk or severity of adverse effects can be increased when DPDPE is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when DPDPE is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when DPDPE is combined with Tilidine.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with DPDPE.Approved
TizanidineThe risk or severity of adverse effects can be increased when DPDPE is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when DPDPE is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when DPDPE is combined with Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with DPDPE.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when DPDPE is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when DPDPE is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when DPDPE is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with DPDPE.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with DPDPE.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with DPDPE.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with DPDPE.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when DPDPE is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with DPDPE.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when DPDPE is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when DPDPE is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when DPDPE is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with DPDPE.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when DPDPE is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with DPDPE.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with DPDPE.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with DPDPE.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when DPDPE is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when DPDPE is combined with Triprolidine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with DPDPE.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with DPDPE.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with DPDPE.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with DPDPE.Approved
UlaritideThe risk or severity of adverse effects can be increased when DPDPE is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with DPDPE.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with DPDPE.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with DPDPE.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with DPDPE.Approved
VenlafaxineDPDPE may increase the serotonergic activities of Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when DPDPE is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when DPDPE is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when DPDPE is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when DPDPE is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when DPDPE is combined with Xenon.Experimental
XipamideThe risk or severity of adverse effects can be increased when DPDPE is combined with Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when DPDPE is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with DPDPE.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when DPDPE is combined with Ziconotide.Approved
ZimelidineDPDPE may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with DPDPE.Approved
ZolazepamThe risk or severity of adverse effects can be increased when DPDPE is combined with Zolazepam.Vet Approved
ZolpidemDPDPE may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when DPDPE is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with DPDPE.Approved
ZotepineThe risk or severity of adverse effects can be increased when DPDPE is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with DPDPE.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C20164
ChemSpider
94592
BindingDB
21008
ChEBI
73356
ChEMBL
CHEMBL31421
Wikipedia
DPDPE

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00632 mg/mLALOGPS
logP0.59ALOGPS
logP-1ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)3.39ChemAxon
pKa (Strongest Basic)7.73ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area199.95 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity168.07 m3·mol-1ChemAxon
Polarizability65.64 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893]

Drug created on March 03, 2013 17:42 / Updated on December 01, 2017 16:10